Background Replacement of carmustine (BCNU) in the BEAM regimen (BCNU, etoposide,
cytarabine, melphalan) with bendamustine (BendaEAM) before autologous stem cell …

Purpose We investigated the in vitro toxicity of bendamustine and fludarabine to
hematopoietic progenitors and stem cells from healthy donors. Methods Clonogenic agar …

Chemotherapeutic agents without cross-resistance to prior therapies may enhance PBSC
collection and improve patient outcomes by exacting a more potent direct antitumor effect …

The remarkable evolution of hematopoietic stem cell transplant (HSCT) over the years
driven by the advances in donor selection, conditioning regimen, supportive care, GVHD …

e18511 Background: We previously reported the use of fludarabine, rituximab and
cyclophosphamide as a nonmyeloablative conditioning for lymphomas (Khouri et al, Blood …

Simple Summary Bendamustine is a chemotherapeutic agent used to treat a variety of
cancers. It has recently been used in the context of allogeneic hematopoietic cell …

Over the last 30 years, BEAM has been the most widely used conditioning regimen before
autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with Hodgkin …

We evaluate the safety of bendamustine as a bridge to stem cell transplantation (SCT) in
patients with relapsed/refractory lymphoma and residual disease after salvage therapy …

We have read the paper by Chantepie et al. 1 evaluating safety of benadamustine-based
conditioning prior to autologous stem cell transplantation (ASCT) with great interest. Authors …

Background We previously reported the use of BFR, with phase 1 escalating daily doses of
70, 90, 110, or 130 mg/m 2 of bendamustine daily x 3 days prior to transplantation without …